Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Lineage Cell Therapeutics (LCTX) Enterprise Value (2016 - 2025)

Lineage Cell Therapeutics (LCTX) has 16 years of Enterprise Value data on record, last reported at -$62.2 million in Q4 2025.

  • For Q4 2025, Enterprise Value fell 26.4% year-over-year to -$62.2 million; the TTM value through Dec 2025 reached -$62.2 million, down 26.4%, while the annual FY2025 figure was -$62.2 million, 26.4% down from the prior year.
  • Enterprise Value reached -$62.2 million in Q4 2025 per LCTX's latest filing, down from -$41.7 million in the prior quarter.
  • Across five years, Enterprise Value topped out at -$31.4 million in Q4 2023 and bottomed at -$98.5 million in Q4 2022.
  • Average Enterprise Value over 5 years is -$55.5 million, with a median of -$49.2 million recorded in 2024.
  • Peak YoY movement for Enterprise Value: crashed 217.54% in 2021, then soared 68.16% in 2023.
  • A 5-year view of Enterprise Value shows it stood at -$66.2 million in 2021, then tumbled by 48.8% to -$98.5 million in 2022, then skyrocketed by 68.16% to -$31.4 million in 2023, then tumbled by 56.7% to -$49.2 million in 2024, then dropped by 26.4% to -$62.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for Enterprise Value were -$62.2 million in Q4 2025, -$41.7 million in Q3 2025, and -$43.6 million in Q2 2025.